64049MAA8
Neogenomics, Inc.
Could not find a ticker for this position, may be a filing error
A laboratory that focuses exclusively on cancer testing, helping oncologists and pathologists diagnose tumors and choose treatments through genetic and molecular analysis. Founded in 2001 in Fort Myers, Florida, by a pathologist and a healthcare executive, it has grown into one of the largest oncology-focused reference labs in the United States. The name blends "neo" — Greek for "new" — with "genomics," a nod to the modern genetic techniques at its core.
CONVERTIBLEUnderlying: NEOCUSIP: 64049MAA8HealthcareUS1 derivative reporter
1.25% Convertible Senior Notes due May 1, 2025
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
